Furthermore, palmitoylation of proteins on the surface of AML-EVs activates Toll-like receptor 2 and thus triggers Akt/mTOR-dependent induction of M-MDSCs, making targeted protein palmitoylation a possible therapeutic target for improving the immune response in AML [178]. The gene discussed is AKT1; the disease is acute myeloid leukemia.